Researchers assess whether blood plasma product could reduce hemorrhaging, improve survival rate of trauma patients

Cryoprecipitate, frozen blood component prepared from plasma, is being studied to see if it can reduce deaths from hemorrhaging in trauma patients. (Getty Images)

The early use of a highly concentrated blood plasma called cryoprecipitate that could reduce deaths from hemorrhaging in trauma patients is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth) as part of an international trial.

The UTHealth Center for Translational Injury Research is launching the Houston site of the international CRYOSTAT-2 trial at Memorial Hermann-Texas Medical Center.

Read the full story, featuring Dr. Cotton…

September 2, 2020